Financial News
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
May 03, 2023 at 14:20 PM EDT
Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
More News
View More
Snap-on Incorporated: Snap It Up Quick, New Highs Will Come Soon
Today 10:48 EDT
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
October 18, 2025
Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
October 18, 2025
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
